Lung cancer is the third most common cancer in the UK, with around 48,500 people diagnosed each year. There are two main types of lung cancer – small cell lung cancer and non small cell lung cancer – depending on how the cells look under the microscope.
The main symptoms are a cough, shortness of breath and weight loss.
3 new cancer treatments have now been approved by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland, including 2 breast cancer treatments and 1 for lung cancer.
A new treatment for some people with a type of non small cell lung cancer (NSCLC) will now be routinely available on the NHS in England, following its approval by the National Institute of Health and Care Excellence (NICE).
Charlie Swanton, our chief clinician, headed to the world’s most important climate change conference to talk about the links between pollution and lung cancer in never smokers…
More than 600 people in England with a form of lung cancer could benefit from the innovative drug osimertinib (Tagrisso) after its approval by the National Institute for Health and Care Excellence.
Selpercatinib will expand treatment options available for people with RET fusion positive non small cell lung cancer on the NHS in England.
Three new cancer drugs have been given the go-ahead by the Scottish Medicines Consortium (SMC) for routine use in Scotland, two for non small cell lung cancer and one for Hodgkin lymphoma, but a fourth has been rejected.
The Medicines and Healthcare products Regulatory Agency has approved the first-of-its-kind drug sotorasib for some people with non small cell lung cancer.
The first participants have taken part in a new research trial that aims to save lives by detecting lung cancer at an earlier stage when it is more treatable.
Reluctance to attend hospital tests and come forward about symptoms could be contributing to delays in lung cancer diagnosis.